Direct antithrombins

New perspectives in cardiovascular medicine

M. Lettino, V. Toschi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Thrombin converts fibrinogen to fibrin and is the most powerful activator of platelets thus playing a crucial role in arterial and venous thrombosis. The limitations of heparin, largely used in the therapy of arterial and venous thromboembolism, has prompted the development of new antithrombotic drugs, able to directly inhibit thrombin. They comprise hirudin, bivalirudin and argatroban, which arc antithrombins for parenteral use, and the orally active ximelagatran which, once absorbed, is converted to the active compound melagatran. Hirudin is a polypeptide able to irreversibly block both the active site and the fibrin(ogen) binding site of thrombin; bivalirudin, a synthetic hirudin derivative, has the same binding sites of hirudin to thrombin but has a shorter pharmacological action and is safer for clinical use. Several clinical trials which tested these drugs in acute coronary syndromes, coronary angioplasty and venous thromboembolism, demonstrate that hirudin and bivalirudin are superior to heparin in significantly reducing cardiac major events. The advantage of hirudin and bivalirudin over heparin was also confirmed in adjuncts to thrombolytic therapy as well as in percutaneous angioplasty relating to thrombotic events but not to restenosis. Hirudin was also significantly better than both unfractionated heparin and low molecular weight heparin (LMWH) in the prophylaxis of venous thromboembolism in patients undergoing elective arthroplasty. Major bleeding associated to hirudin was not different from that observed with heparin. Preliminary data also indicate that melagatran/ximelagatran may be used in the prophylaxis of venous thromboembolism and in the prevention of arterial embolism in patients with non-valvular atrial fibrillation.

Original languageEnglish
Pages (from-to)267-275
Number of pages9
JournalCurrent Medicinal Chemistry: Cardiovascular and Hematological Agents
Volume2
Issue number3
DOIs
Publication statusPublished - Jul 2004

Fingerprint

Hirudins
Antithrombins
Medicine
Venous Thromboembolism
Heparin
Thrombin
Fibrin
Angioplasty
Binding Sites
Low Molecular Weight Heparin
Thrombolytic Therapy
Acute Coronary Syndrome
Embolism
Venous Thrombosis
Arthroplasty
Pharmaceutical Preparations
Fibrinogen
Atrial Fibrillation
Catalytic Domain
Blood Platelets

Keywords

  • Acute coronary syndromes
  • Anticoagulants
  • Hirudin
  • Thrombin
  • Thrombosis
  • Venous thromboembolism

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Direct antithrombins : New perspectives in cardiovascular medicine. / Lettino, M.; Toschi, V.

In: Current Medicinal Chemistry: Cardiovascular and Hematological Agents, Vol. 2, No. 3, 07.2004, p. 267-275.

Research output: Contribution to journalArticle

@article{912bcf9c05a74f229c0c7542114d4570,
title = "Direct antithrombins: New perspectives in cardiovascular medicine",
abstract = "Thrombin converts fibrinogen to fibrin and is the most powerful activator of platelets thus playing a crucial role in arterial and venous thrombosis. The limitations of heparin, largely used in the therapy of arterial and venous thromboembolism, has prompted the development of new antithrombotic drugs, able to directly inhibit thrombin. They comprise hirudin, bivalirudin and argatroban, which arc antithrombins for parenteral use, and the orally active ximelagatran which, once absorbed, is converted to the active compound melagatran. Hirudin is a polypeptide able to irreversibly block both the active site and the fibrin(ogen) binding site of thrombin; bivalirudin, a synthetic hirudin derivative, has the same binding sites of hirudin to thrombin but has a shorter pharmacological action and is safer for clinical use. Several clinical trials which tested these drugs in acute coronary syndromes, coronary angioplasty and venous thromboembolism, demonstrate that hirudin and bivalirudin are superior to heparin in significantly reducing cardiac major events. The advantage of hirudin and bivalirudin over heparin was also confirmed in adjuncts to thrombolytic therapy as well as in percutaneous angioplasty relating to thrombotic events but not to restenosis. Hirudin was also significantly better than both unfractionated heparin and low molecular weight heparin (LMWH) in the prophylaxis of venous thromboembolism in patients undergoing elective arthroplasty. Major bleeding associated to hirudin was not different from that observed with heparin. Preliminary data also indicate that melagatran/ximelagatran may be used in the prophylaxis of venous thromboembolism and in the prevention of arterial embolism in patients with non-valvular atrial fibrillation.",
keywords = "Acute coronary syndromes, Anticoagulants, Hirudin, Thrombin, Thrombosis, Venous thromboembolism",
author = "M. Lettino and V. Toschi",
year = "2004",
month = "7",
doi = "10.2174/1568016043356291",
language = "English",
volume = "2",
pages = "267--275",
journal = "Current Medicinal Chemistry: Cardiovascular and Hematological Agents",
issn = "1568-0169",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Direct antithrombins

T2 - New perspectives in cardiovascular medicine

AU - Lettino, M.

AU - Toschi, V.

PY - 2004/7

Y1 - 2004/7

N2 - Thrombin converts fibrinogen to fibrin and is the most powerful activator of platelets thus playing a crucial role in arterial and venous thrombosis. The limitations of heparin, largely used in the therapy of arterial and venous thromboembolism, has prompted the development of new antithrombotic drugs, able to directly inhibit thrombin. They comprise hirudin, bivalirudin and argatroban, which arc antithrombins for parenteral use, and the orally active ximelagatran which, once absorbed, is converted to the active compound melagatran. Hirudin is a polypeptide able to irreversibly block both the active site and the fibrin(ogen) binding site of thrombin; bivalirudin, a synthetic hirudin derivative, has the same binding sites of hirudin to thrombin but has a shorter pharmacological action and is safer for clinical use. Several clinical trials which tested these drugs in acute coronary syndromes, coronary angioplasty and venous thromboembolism, demonstrate that hirudin and bivalirudin are superior to heparin in significantly reducing cardiac major events. The advantage of hirudin and bivalirudin over heparin was also confirmed in adjuncts to thrombolytic therapy as well as in percutaneous angioplasty relating to thrombotic events but not to restenosis. Hirudin was also significantly better than both unfractionated heparin and low molecular weight heparin (LMWH) in the prophylaxis of venous thromboembolism in patients undergoing elective arthroplasty. Major bleeding associated to hirudin was not different from that observed with heparin. Preliminary data also indicate that melagatran/ximelagatran may be used in the prophylaxis of venous thromboembolism and in the prevention of arterial embolism in patients with non-valvular atrial fibrillation.

AB - Thrombin converts fibrinogen to fibrin and is the most powerful activator of platelets thus playing a crucial role in arterial and venous thrombosis. The limitations of heparin, largely used in the therapy of arterial and venous thromboembolism, has prompted the development of new antithrombotic drugs, able to directly inhibit thrombin. They comprise hirudin, bivalirudin and argatroban, which arc antithrombins for parenteral use, and the orally active ximelagatran which, once absorbed, is converted to the active compound melagatran. Hirudin is a polypeptide able to irreversibly block both the active site and the fibrin(ogen) binding site of thrombin; bivalirudin, a synthetic hirudin derivative, has the same binding sites of hirudin to thrombin but has a shorter pharmacological action and is safer for clinical use. Several clinical trials which tested these drugs in acute coronary syndromes, coronary angioplasty and venous thromboembolism, demonstrate that hirudin and bivalirudin are superior to heparin in significantly reducing cardiac major events. The advantage of hirudin and bivalirudin over heparin was also confirmed in adjuncts to thrombolytic therapy as well as in percutaneous angioplasty relating to thrombotic events but not to restenosis. Hirudin was also significantly better than both unfractionated heparin and low molecular weight heparin (LMWH) in the prophylaxis of venous thromboembolism in patients undergoing elective arthroplasty. Major bleeding associated to hirudin was not different from that observed with heparin. Preliminary data also indicate that melagatran/ximelagatran may be used in the prophylaxis of venous thromboembolism and in the prevention of arterial embolism in patients with non-valvular atrial fibrillation.

KW - Acute coronary syndromes

KW - Anticoagulants

KW - Hirudin

KW - Thrombin

KW - Thrombosis

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=3042699985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042699985&partnerID=8YFLogxK

U2 - 10.2174/1568016043356291

DO - 10.2174/1568016043356291

M3 - Article

VL - 2

SP - 267

EP - 275

JO - Current Medicinal Chemistry: Cardiovascular and Hematological Agents

JF - Current Medicinal Chemistry: Cardiovascular and Hematological Agents

SN - 1568-0169

IS - 3

ER -